GlassScriptPhysician profile
Nomin Park
NPI 1801645742
$2,265.89
in general payments reported to CMS, 2019-2025
22 companies · $2,205 in 2025
The $2,205 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $61.07 · 2025: $2,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,265.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $341.34 | 2025 | Repatha, Evenity, Otezla |
| Novo Nordisk INC | $286.82 | 2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $231.16 | 2024-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $189.96 | 2025 | Rexulti |
| Ardelyx, INC. | $173.68 | 2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $168.39 | 2025 | Airsupra, Farxiga |
| Abbvie INC. | $141.86 | 2025 | |
| Sumitomo Pharma America, INC. | $109.38 | 2025 | Gemtesa |
| Pfizer INC. | $71.32 | 2025 | |
| Astellas Pharma US INC | $68.14 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.90 | 2025 | Xifaxan |
| Paratek Pharmaceuticals, INC. | $61.19 | 2025 | Nuzyra, Xhance |
| Exact Sciences Corporation | $57.34 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.40 | 2025 | Caplyta |
| Lundbeck LLC | $51.92 | 2025 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $45.55 | 2025 | |
| Aimmune Therapeutics, INC. | $44.80 | 2025 | Zenpep |
| Vanda Pharmaceuticals INC. | $24.13 | 2025 | Fanapt, Hetlioz |
| Dexcom, INC. | $22.14 | 2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $20.97 | 2025 | Auvelity |
| Azurity Pharmaceuticals, INC. | $18.70 | 2025 | Horizant |
| Merck Sharp & Dohme LLC | $13.80 | 2025 | Gardasil 9, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nomin Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.